ライフサイエンスコーパス: ibalizumab

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 envelope glycoprotein gp120 are resistant to ibalizumab.

2 al to gp120 V5 may restore susceptibility to ibalizumab.

3 IV-1 variants with reduced susceptibility to ibalizumab.

4 , including 10 strains resistant to parental ibalizumab.

5 Both maraviroc and ibalizumab are being studied for prevention of HIV-1 tra

6 3 in domain 2 were found to be important for ibalizumab binding, with E77 and S79 in domain 1 also co

7 cular, clones with reduced susceptibility to ibalizumab contained fewer potential asparagine-linked g

8 Thus, a characterization of the ibalizumab epitope was conducted in an attempt to gain i

9 Ibalizumab (formerly TNX-355) is a first-in-class, monoc

10 In clinical trials, ibalizumab has demonstrated anti-HIV-1 activity in patie

11 ein not only provide an appreciation for why ibalizumab has not had significant adverse immunological

12 The postattachment inhibitor ibalizumab has shown antiviral activity in phase 1 and 2

13 hat combine the HIV-1 inhibitory activity of ibalizumab (iMab), a humanized mAb directed to domain 2

14 Ibalizumab is a humanized monoclonal antibody that binds

15 Ibalizumab is a humanized monoclonal antibody that binds

16 t by engineering an N-linked glycan into the ibalizumab light chain at a position spatially proximal

17 lls a void between the gp120 V5 loop and the ibalizumab light chain, perhaps causing steric hindrance

18 A 9-week phase Ib study adding ibalizumab monotherapy to failing drug regimens led to t

19 Functionally, viruses with reduced ibalizumab susceptibility also displayed high levels of

20 Individual env clones exhibiting reduced ibalizumab susceptibility contained multiple amino acid

21 The reduction in ibalizumab susceptibility due to the loss of V5 PNGSs wa

22 s) in variable region 5 (V5) than did paired ibalizumab-susceptible clones.

23 iviral activity, safety, and tolerability of ibalizumab treatment.

24 Indeed, one such ibalizumab variant neutralized 100% of 118 diverse HIV-1

25 mouse monoclonal antibody that competes with ibalizumab, was localized entirely within domain 2 on re

26 this void contributes to HIV-1 resistance to ibalizumab, we reasoned that 'refilling' it by engineeri

27 Viruses with reduced susceptibility to ibalizumab were found to exhibit reduced susceptibility

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。